Carbonic anhydrase IX, a marker of hypoxia: Correlation with clinical outcome in transitional cell carcinoma of the bladder

Oncology Reports

Volumn 11, Issue 5, 2004, Pages 1005-1010

  Hussain, Syed A ^a   Palmer, Daniel H ^a   Ganesan, Raji ^b   Hiller, Louise ^c   Gregory, John ^b   Murray, Paul G ^a   Pastorek, Jaromir ^d   Young, Lawrence ^a   James, Nicholas D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Bladder cancer; Carbonic anhydrase IX; Hypoxia; Prognostic marker

Indexed keywords

CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANOXIA; ARTICLE; BLADDER TUMOR; ENZYMOLOGY; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROBABILITY; PROGNOSIS; SURVIVAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 12344260056     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.5.1005     Document Type: Article

References (37)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52: 23-47, 2002. (Pubitemid 34110469)
2. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7-33, 2000. (Pubitemid 30072093)
3. Freiha F, Reese J and Torti FM: A randomised trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155: 495-500, 1996. (Pubitemid 26023531)
4. International Collaboration of Trialists: Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle invasive bladder cancer: a randomised controlled trial. Lancet 354: 533-540, 1999.
5. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S and Hannisdal E: Five-year follow up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 155: 1903-1906, 1996. (Pubitemid 26144081)
6. Stockle M, Wellek S, Meyenburg W, et al: Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 48: 868-875, 1996.
7. Millikan R, Dinney C, Swanson D, Sweeney P, Ro J, Smith T, Williams D and Log C: Integrated therapy for locally advanced bladder cancer: final report of a randomised trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. JCO 19: 4005-4013, 2001. (Pubitemid 32976686)
8. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, De Vere White RW, Sarosdy MF, Wood DP Jr, Raghavan D and Crawford ED: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349: 859-866, 2003. (Pubitemid 37025405)
9. Advanced Bladder Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361: 1927-1934, 2003.
10. Hussain SA, Ganesan R, Hiller L, Murray P, El-Magraby M, Young LS and James ND: Pro-apoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer 88: 586-592, 2003. (Pubitemid 36363369)
11. Hussain SA, Ganesan R, Hiller L, Cooke PW, Murray P, Young LS and James ND: BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in muscle invasive transitional cell carcinoma of the bladder. Oncol Rep 10: 571-576, 2003.
12. Cooke PW, James ND, Ganesan R, Burton A, Young LS and Wallace DM: BCL2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. Br J Urol Int 85: 829-835, 2000. (Pubitemid 30242786)
13. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379: 88-91, 1996. (Pubitemid 26008141)
14. Brizel DM, Scully SP, Harrelson JM, et al: Tumor oxygenation predicts for likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941-943, 1996. (Pubitemid 26065381)
15. Hockel M, Schlenger K, Aral B, et al: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515, 1996. (Pubitemid 26330463)
16. Reynolds TY, Rockwell S and Glazer PM: Genetic instability induced by the tumor microenvironment. Cancer Res 56: 5754-5757, 1996. (Pubitemid 26422184)
17. Kim CY, Tsai MH, Osmanian C, et al: Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res 57: 4200-4204, 1997. (Pubitemid 27413423)
18. Hockel M, Knoop C, Schlenger K, et al: Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv Exp Med Biol 345: 445-450, 1994. (Pubitemid 24145783)
19. Fyles AW, Milosevic M, Wong R, et al: Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48: 149-156, 1998. (Pubitemid 28423786)
20. Knocke TH, Weitmann HD, Feldmann HJ, et al: Intratumoral pO2 measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 53: 99-104, 1999.
21. Brizel DM, Rosner GL, Prosnitz LR, et al: Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys 32: 1121-1125, 1995.
22. Nordsmark M, Overgaard M and Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31-39, 1996. (Pubitemid 26396294)
23. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L and Hill RP: Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20: 680-687, 2002. (Pubitemid 34111374)
24. Swinson DEB, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL and O'Byrne KJ: Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. JCO, Feb 1, 473-482, 2003.
25. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P and Harris AL: Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. JCO Aug 15, 3660-3668, 2001.
26. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist ASE, Pop LAM, van den Hoogen FJA, De Wilde PCM, Bussink J, Raleigh JA and van der Kogel AJ: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62: 7066-7074, 2002. (Pubitemid 35424102)
27. Hussain SA, Moffitt DD, Glaholm JG, Peake D, Wallace DMA and James ND: A phase I/II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. Ann Oncol 12: 929-935, 2001. (Pubitemid 32725764)
28. Wallace DM, Raghavan D, Kelly KA, et al: Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67: 608-615, 1991.
29. Pastorekova S, Zavadova Z, Kostal M, Babusikova O and Zavada J: A novel quasi-viral agent, MaTu, is a two-component system. Virology 187: 620-626, 1992.
30. Greenacre MJ: Theory and Applications of Correspondence Analysis. Academic Press, London, 1984.
31. Kaplan EL and Meier P: Non parametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481, 1958.
32. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J and Smith PG: Design and analysis of randomised clinical trials requiring prolonged observation of each patient II. Analysis and example. Br J Cancer 35: 1-39, 1977. (Pubitemid 8018922)
33. Cox DR: Regression models and life tables. J Roy Statist Soc B 34: 187-220, 1972.
34. Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J, Ratcliffe PJ, Cranston D and Harris AL: The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 86: 1276-1282, 2002.
35. Hoskin PJ, Sibtain A, Daley FM and Wilson GD: GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89: 1290-1297, 2003. (Pubitemid 37363419)
36. Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y and Oosterwijk E: MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 81: 741-746, 1999. (Pubitemid 29458875)
37. Overgaard J and Horsman MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6: 10-21, 1996. (Pubitemid 26029371)